Safety, immunogenicity and non-interference of concomitant Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV®) and measles or measles-mumps-rubella vaccines in 8-9 months-old Indian children

• Hauptverfasser: Krishna Mohan Vadrevu (Verfasst von), Raju Dugyala (Verfasst von), Niranjana Shamulinga Mahantashetti (Verfasst von), Vasant Khalatkar (Verfasst von), Krishna Murthy (Verfasst von), Sandeep Mogre (Verfasst von), Monjori Mitra (Verfasst von)
• Format: Buch
• Veröffentlicht: Taylor & Francis Group, 2022-12-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

We evaluated safety, reactogenicity, and immunogenicity when the WHO-prequalified single-dose Typhoid Vi-polysaccharide conjugate vaccine, Typbar-TCV®, was administered concomitantly with measles (MV) or measles-mumps-rubella (MMR) vaccines in 8- or 9-month-old children. We enrolled 493 children who...